Garcia PM, Kalish LA, Pitt J, Minkoff H, Quinn TC, Burchett SK, Kornegay J, Jackson B, Moye J, Hanson C, Zorrilla C, Lew JF: Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and infants transmission study group. N Engl J Med. 1999, 341: 394-402. 10.1056/NEJM199908053410602.
Das M, Chu PL, Santos G-M, Scheer S, Vittinghoff E, McFarland W, Colfax GN: Decreases in community viral load are accompanied by reductions in new HIV Infections in San Francisco. PLoS One. 2010, 5: e11068-10.1371/journal.pone.0011068.
Wood E, Kerr T, Marshall BDL, Li K, Zhang R, Hogg RS, Harrigan PR, Montaner JSG: Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study. BMJ. 2009, 338: b1649-b1649. 10.1136/bmj.b1649.
Montaner JSG, Lima VD, Barrios R, Yip B, Wood E, Kerr T, Shannon K, Harrigan PR, Hogg RS, Daly P, Kendall P: Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet. 2010, 376: 532-539. 10.1016/S0140-6736(10)60936-1.
Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG: Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet. 2009, 373: 48-57. 10.1016/S0140-6736(08)61697-9.
Charlebois ED, Das M, Porco TC, Havlir DV: The effect of expanded antiretroviral treatment strategies on the HIV epidemic among men who have sex with men in San Francisco. Clin Infect Dis. 2011, 52: 1046-1049. 10.1093/cid/cir085.
Sorensen SW, Sansom SL, Brooks JT, Marks G, Begier EM, Buchacz K, Dinenno EA, Mermin JH, Kilmarx PH: A mathematical model of comprehensive test-and-treat services and HIV incidence among men who have sex with men in the United States. PLoS One. 2012, 7: e29098-10.1371/journal.pone.0029098.
Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, Hakim JG, Kumwenda J, Grinsztejn B, Pilotto JHS, Godbole SV, Mehendale S, Chariyalertsak S, Santos BR, Mayer KH, Hoffman IF, Eshleman SH, Piwowar-Manning E, Wang L, Makhema J, Mills LA, de Bruyn G, Sanne I, Eron J, Gallant J, Havlir D, Swindells S, Ribaudo H, Elharrar V, Burns D, et al: Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011, 365: 493-505. 10.1056/NEJMoa1105243.
Coates TJ, Richter L, Caceres C: Behavioural strategies to reduce HIV transmission: how to make them work better. Lancet. 2008, 372: 669-684. 10.1016/S0140-6736(08)60886-7.
Hull MW, Wu Z, Montaner JSG: Optimizing the engagement of care cascade: a critical step to maximize the impact of HIV treatment as prevention. Curr Opin HIV AIDS. 2012, 7: 579-586. 10.1097/COH.0b013e3283590617.
Mathers BM, Degenhardt L, Phillips B, Wiessing L, Hickman M, Strathdee SA, Wodak A, Panda S, Tyndall M, Toufik A, Mattick RP, 2007 Reference Group to the UN on HIV and Injecting Drug Use: Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet. 2008, 372: 1733-1745. 10.1016/S0140-6736(08)61311-2.
Cohen MS, Muessig KE, Smith MK, Powers KA, Kashuba ADM: Antiviral agents and HIV prevention: controversies, conflicts, and consensus. AIDS. 2012, 26: 1585-1598. 10.1097/QAD.0b013e3283543e83.
Hull MW, Montaner J: Antiretroviral therapy: a key component of a comprehensive HIV prevention strategy. Curr HIV/AIDS Rep. 2011, 8: 85-93. 10.1007/s11904-011-0076-6.
Pollini RA, Alvelais J, Gallardo M, Vera A, Lozada R, Magis-Rodriquez C, Strathdee SA: The harm inside: injection during incarceration among male injection drug users in Tijuana, Mexico. Drug Alcohol Depend. 2009, 103: 52-58. 10.1016/j.drugalcdep.2009.03.005.
Malliori M, Sypsa V, Psichogiou M, Touloumi G, Skoutelis A, Tassopoulos N, Hatzakis A, Stefanis C: A survey of bloodborne viruses and associated risk behaviours in Greek prisons. Addiction. 1998, 93: 243-251. 10.1046/j.1360-0443.1998.9322438.x.
Milloy M-JS, Buxton J, Wood E, Li K, Montaner JSG, Kerr T: Elevated HIV risk behaviour among recently incarcerated injection drug users in a Canadian setting: a longitudinal analysis. BMC Public Health. 2009, 9: 156-10.1186/1471-2458-9-156.
Darke S, Kaye S, Finlay-Jones R: Drug use and injection risk-taking among prison methadone maintenance patients. Addiction. 1998, 93: 1169-1175. 10.1046/j.1360-0443.1998.93811695.x.
López-Zetina J, Kerndt P, Ford W, Woerhle T, Weber M: Prevalence of HIV and hepatitis B and self-reported injection risk behavior during detention among street-recruited injection drug users in Los Angeles County, 1994–1996. Addiction. 2001, 96: 589-595.
Centers for Disease Control and Prevention (CDC): HIV transmission among male inmates in a state prison system--Georgia, 1992–2005. MMWR Morb Mortal Wkly Rep. 2006, 55: 421-426.
Taylor A, Goldberg D, Emslie J, Wrench J, Gruer L, Cameron S, Black J, Davis B, McGregor J, Follett E: Outbreak of HIV infection in a Scottish prison. BMJ. 1995, 310: 289-292. 10.1136/bmj.310.6975.289.
Dolan KA, Wodak A: HIV transmission in a prison system in an Australian State. Med J Aust. 1999, 171: 14-17.
Bobrik A, Danishevski K, Eroshina K, McKee M: Prison health in Russia: the larger picture. J Public Health Pol. 2005, 26: 30-59. 10.1057/palgrave.jphp.3200002.
The Global Commission On Drug Policy: The War on Drugs and HIV/AIDS. 2012, Global Commission on Drug Policy, 1-24.
Jürgens R, Nowak M, Day M: HIV and incarceration: prisons and detention. J Int AIDS Soc. 2011, 14: 26-10.1186/1758-2652-14-26.
Baillargeon J, Giordano TP, Rich JD, Wu ZH, Wells K, Pollock BH, Paar DP: Accessing antiretroviral therapy following release from prison. JAMA. 2009, 301: 848-857. 10.1001/jama.2009.202.
Westergaard RP, Kirk GD, Richesson DR, Galai N, Mehta SH: Incarceration predicts virologic failure for hiv-infected injection drug users receiving antiretroviral therapy. Clin Infect Dis. 2011, 53: 725-731. 10.1093/cid/cir491.
Strathdee S, Palepu A, Cornelisse PG, Yip B, O'shaughnessy MV, Montaner JS, Schechter MT, Hogg RS: Barriers to use of free antiretroviral therapy in injection drug users. JAMA. 1998, 280: 547-549. 10.1001/jama.280.6.547.
Kerr T, Marshall BDL, Milloy M-J, Zhang R, Guillemi S, Montaner JSG, Wood E: Patterns of heroin and cocaine injection and plasma HIV-1 RNA suppression among a long-term cohort of injection drug users. Drug Alcohol Depend. 2012, 124: 1-5. 10.1016/j.drugalcdep.2012.01.012.
Krusi A, Milloy M-J, Kerr T, Zhang R, Guillemi S, Hogg R, Montaner J, Wood E: Ongoing drug use and outcomes from highly active antiretroviral therapy among injection drug users in a Canadian setting. Antivir Ther (Lond). 2010, 15: 789-796. 10.3851/IMP1614.
Milloy M-J, Kerr T, Buxton J, Rhodes T, Guillemi S, Hogg R, Montaner J, Wood E: Dose–response effect of incarceration events on nonadherence to HIV antiretroviral therapy among injection drug users. J Infect Dis. 2011, 203: 1215-1221. 10.1093/infdis/jir032.
Milloy M-J, Kerr T, Buxton J, Rhodes T, Krusi A, Guillemi S, Hogg R, Montaner J, Wood E: Social and environmental predictors of plasma HIV RNA rebound among injection drug users treated with antiretroviral therapy. J Acquir Immune Defic Syndr. 2012, 59: 393-399. 10.1097/QAI.0b013e3182433288.
Wood E, Hogg RS, Lima VD, Kerr T, Yip B, Marshall BDL, Montaner JSG: Highly active antiretroviral therapy and survival in HIV-infected injection drug users. JAMA. 2008, 300: 550-554. 10.1001/jama.300.5.550.
Sangsari S, Milloy M-J, Ibrahim A, Kerr T, Zhang R, Montaner J, Wood E: Physician experience and rates of plasma HIV-1 RNA suppression among illicit drug users: an observational study. BMC Infect Dis. 2012, 12: 22-10.1186/1471-2334-12-22.
Milloy M-J, Kerr T, Bangsberg DR, Buxton J, Parashar S, Guillemi S, Montaner J, Wood E: Homelessness as a structural barrier to effective antiretroviral therapy among HIV-seropositive illicit drug users in a Canadian setting. AIDS Patient Care STDS. 2012, 26: 60-67. 10.1089/apc.2011.0169.
Low-Beer S, Yip B, O'Shaughnessy MV, Hogg RS, Montaner JS: Adherence to triple therapy and viral load response. JAIDS J Acquir Immune Defic Syndr. 2000, 23: 360-361.
Palepu A, Yip B, Miller C, Strathdee SA, O'Shaughnessy MV, Montaner JS, Hogg RS: Factors associated with the response to antiretroviral therapy among HIV-infected patients with and without a history of injection drug use. AIDS. 2001, 15: 423-424. 10.1097/00002030-200102160-00021.
Wood E, Montaner JSG, Yip B, Tyndall MW, Schechter MT, O'shaughnessy MV, Hogg RS: Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users. CMAJ. 2003, 169: 656-661.
Finucane MM, Samet JH, Horton NJ: Translational methods in biostatistics: linear mixed effect regression models of alcohol consumption and HIV disease progression over time. Epidemiol Perspect Innov. 2007, 4: 8-10.1186/1742-5573-4-8.
Maldonado G, Greenland S: Simulation study of confounder-selection strategies. Am J Epidemiol. 1993, 138: 923-936.
Lima V, Fernandes K, Rachlis B, Druyts E, Montaner J, Hogg R: Migration adversely affects antiretroviral adherence in a population-based cohort of HIV/AIDS patients. Soc Sci Med. 2009, 68: 1044-1049. 10.1016/j.socscimed.2008.12.043.
Marshall BDL, Kerr T, Shoveller JA, Patterson TL, Buxton JA, Wood E: Homelessness and unstable housing associated with an increased risk of HIV and STI transmission among street-involved youth. Health Place. 2009, 15: 753-760.
Sobel ME: Asymptotic intervals for indirect effects in structural equations models. Sociological methodology. Edited by: Leinhart S. 1982, San Francisco, California: Jossey-Bass, 290-312.
MacKinnon DP, Lockwood CM, Hoffman JM, West SG, Sheets V: A comparison of methods to test mediation and other intervening variable effects. Psychol Methods. 2002, 7: 83-104.
Hadland SE, Milloy M-J, Kerr T, Zhang R, Guillemi S, Hogg RS, Montaner JS, Wood E: Young age predicts poor antiretroviral adherence and viral load suppression among injection drug users. AIDS Patient Care STDS. 2012, 26: 274-280. 10.1089/apc.2011.0196.
Kuyper L, Milloy M-J, Marshall BDL, Zhang R, Kerr T, Montaner JSG, Wood E: Does initiation of HIV antiretroviral therapy influence patterns of syringe lending among injection drug users?. Addict Behav. 2011, 36: 560-563. 10.1016/j.addbeh.2011.01.022.
Kerr T, Small W, Buchner C, Zhang R, Li K, Montaner J, Wood E: Syringe sharing and HIV incidence among injection drug users and increased access to sterile syringes. Am J Public Health. 2010, 100: 1449-1453. 10.2105/AJPH.2009.178467.
Small W, Wood E, Betteridge G, Montaner J, Kerr T: The impact of incarceration upon adherence to HIV treatment among HIV-positive injection drug users: a qualitative study. AIDS Care. 2009, 21: 708-714. 10.1080/09540120802511869.
Mathers BM, Degenhardt L, Ali H, Wiessing L, Hickman M, Mattick RP, Myers B, Ambekar A, Strathdee SA: HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. Lancet. 2010, 375: 1014-1028. 10.1016/S0140-6736(10)60232-2.
Milloy MJ, Montaner J, Wood E: Barriers to HIV treatment among people who use injection drugs: implications for ‘treatment as prevention’. Curr Opin HIV AIDS. 2012, 7: 332-338. 10.1097/COH.0b013e328354bcc8.
Strathdee SA, Shoptaw S, Dyer TP, Quan VM, Aramrattana A, Substance Use Scientific Committee of the HIV Prevention Trials Network: Towards combination HIV prevention for injection drug users: addressing addictophobia, apathy and inattention. Curr Opin HIV AIDS. 2012, 7: 320-325. 10.1097/COH.0b013e32835369ad.
Padian NS, McCoy SI, Manian S, Wilson D, Schwartländer B, Bertozzi SM: Evaluation of large-scale combination HIV prevention programs: essential issues. J Acquir Immune Defic Syndr. 2011, 58: e23-e28. 10.1097/QAI.0b013e318227af37.
Dolan K, Kite B, Black E, Aceijas C, Stimson GV: Reference group on HIV/AIDS prevention and care among injecting drug users in developing and transitional countries: HIV in prison in low-income and middle-income countries. Lancet Infect Dis. 2007, 7: 32-41. 10.1016/S1473-3099(06)70685-5.
Spaulding AC, Seals RM, Page MJ, Brzozowski AK, Rhodes W, Hammett TM: HIV/AIDS among inmates of and releasees from US correctional facilities, 2006: declining share of epidemic but persistent public health opportunity. PLoS One. 2009, 4: A16-A21.
Springer S, Friedland G, Doros G, Pesanti E, Altice F: Antiretroviral treatment regimen outcomes among hiv-infected prisoners. HIV Clin Trials. 2007, 8: 205-212. 10.1310/hct0804-205.
Springer SA, Pesanti E, Hodges J, Macura T, Doros G, Altice FL: Effectiveness of antiretroviral therapy among HIV-infected prisoners: reincarceration and the lack of sustained benefit after release to the community. Clin Infect Dis. 2004, 38: 1754-1760. 10.1086/421392.
Davies N, Karstaedt AS: Antiretroviral outcomes in South African prisoners: a retrospective cohort analysis. PLoS One. 2012, 7 (3): e33309-10.1371/journal.pone.0033309.
Older S: Unprecedented effort to seek, test, and treat inmates with HIV: NIH research to improve public health with focus on prison on jail systems across the United States. 2010, NIH News, 1-3.
Flanigan TP, Beckwith CG: The intertwined epidemics of hiv infection, incarceration, and substance abuse: a call to action. J Infect Dis. 2011, 203: 1201-1203. 10.1093/infdis/jir034.
Fazel S, Baillargeon J: The health of prisoners. Lancet. 2011, 377: 956-965. 10.1016/S0140-6736(10)61053-7.
Public Health Branch, Health Services Sector of Correctional Service Canada (CSC): Infectious Disease Surveillance in Canadian Federal Penitentiaries (2007–2008). 2009, Ottawa, Ontario, Canada: Correctional Service Canada, 1-17.
Small W, Kain S, Laliberte N, Schechter MT, O'shaughnessy MV, Spittal PM: Incarceration, addiction and harm reduction: inmates experience injecting drugs in prison. Subst Use Misuse. 2005, 40: 831-843. 10.1081/JA-200030795.
Milloy M-J, Wood E, Small W, Tyndall M, Lai C, Montaner J, Kerr T: Incarceration experiences in a cohort of active injection drug users. Drug Alcohol Rev. 2008, 27: 693-699. 10.1080/09595230801956157.